Semira was 3-years-old when Julia and Rich Hehn adopted her from Ethiopia. She would have died before her 4th birthday without the medical treatment provided by Dr. Kevin Urdahl. Together, we can move closer to saving millions more lives. >>More

While at Seattle BioMed, Dr. Leo Stamatatos and his research team discovered an HIV vaccine candidate that stimulates the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. >>More

The Malaria Clinical Trials Center (MCTC) at Seattle BioMed is looking for healthy volunteers to take part in the upcoming GAP3KO malaria clinical research study. >>See if you are eligible

Seattle BioMed President and Director Alan Aderem has written an op-ed for the Seattle Times about the critical importance of NIH funding in developing infectious disease research . Join us in seeking congressional action.   >>Learn More

Professor John Aitchison is a co-recipient of a $10.9 million grant from the NIH’s Institute of General Medical Sciences to establish a new Biotechnology Resource to aid researchers in interpreting complex biological systems, such as cancer and infectious diseases.   >> More

Mapping a Killer

Mapping a Killer
Someone dies from tuberculosis every 20 seconds, yet there's still no effective vaccine. Our groundbreaking map of the Mycobacterium tuberculosis gene regulatory network lays the foundation for new treatments. >>Learn More

At Seattle BioMed, we are tipping the fight against infectious disease.  We put HIV, tuberculosis and malaria scientists under one roof with systems biology experts to work on our only agenda: to do science that accelerates progress and improves lives. >> Watch our video


Novel Agents Capable of Killing TB Identified

Researchers in the lab of Professor David Sherman, Ph.D., have developed and screened several compounds with antibacterial properties capable of destroying Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. These compounds, called anti-folates, block the folate pathway, which is responsible for the synthesis of the essential cellular building blocks, without which Mtb cannot survive. The results of this study were published in the June issue of the journal Chemistry and Biology.  More >>

A Novel Malaria Vaccine Approach

In September 15th's R&D Magazine, Dr. Stefan Kappe defines the struggles of current malaria vaccines in clinical trials. In order to create a successful malaria vaccine, Kappe and his team developed a GAP vaccine strategy that prohibits the parasite from leaving the liver and causing infection. More>>

News + Events

January 5, 2015

Connect with Us

Stay informed. Sign up for our email newsletter

Find out what the BUZZ is all about.

visit our labs
[ Lab to Life Tour ]